1. Scrip
  2. >>Business

Vertex Secures Rapid Deal In England For CF Triple Therapy

Access Will Be Among Fastest In Europe

 
• By Andrew McConaghie

After a long-standing row with payer NHS England, the rapid market access deal will help Vertex move into growth phase.  

Boston
Vertex's HQ in Boston. The company has resolved its long-running row with NHS England, which will give 7,000 patients in England access to the triple therapy.

Vertex Pharmaceuticals Inc. has struck a market access deal with NHS England for its cystic fibrosis (CF) drug Kaftrio – transforming a years-long bitter stand-off into an agreement that will see patients there receive the triple therapy faster than elsewhere in Europe.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Zelluna Believes Its TCR Tech Can Unlock Natural Killer Cell Potential

 
• By Andrew McConaghie

While CAR-NKs have pivoted towards autoimmune disease, the Norwegian biotech believes its unique platform can deliver in oncology

AstraZeneca COPD Drug Breztri Breezes Through Asthma Trials

 
• By Kevin Grogan

The triple therapy improves lung function in the Phase III KALOS and LOGOS studies

Transient FY26 For Syngene But Momentum In China +1 Projects

 
• By Anju Ghangurde

As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.